BCRX Biocryst Pharmaceuticals Inc

Price (delayed)

$17.26

Market cap

$3.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.2

Enterprise value

$3.13B

Highlights
Biocryst Pharmaceuticals's quick ratio has surged by 100% YoY but it has decreased by 12% QoQ
BCRX's revenue has soared by 80% QoQ but it is down by 33% YoY
The net income has dropped by 81% year-on-year and by 15% since the previous quarter
BCRX's EPS is down by 33% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of BCRX
Market
Shares outstanding
177.7M
Market cap
$3.07B
Enterprise value
$3.13B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
95.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.52
Earnings
Revenue
$32.05M
EBIT
-$185.14M
EBITDA
-$184.43M
Free cash flow
-$175.44M
Per share
EPS
-$1.2
Free cash flow per share
-$0.99
Book value per share
-$0.42
Revenue per share
$0.18
TBVPS
$1.6
Balance sheet
Total assets
$284.43M
Total liabilities
$359.42M
Debt
$289.22M
Equity
-$74.99M
Working capital
$172.57M
Liquidity
Debt to equity
-3.86
Current ratio
2.71
Quick ratio
2.6
Net debt/EBITDA
-0.32
Margins
EBITDA margin
-575.5%
Gross margin
76.6%
Net margin
-653.7%
Operating margin
-577.7%
Efficiency
Return on assets
-83%
Return on equity
-5,272.4%
Return on invested capital
-136.1%
Return on capital employed
-101%
Return on sales
-577.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
1.71%
1 week
10.57%
1 month
1.59%
1 year
277.68%
YTD
131.68%
QTD
9.17%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$32.05M
Gross profit
$24.55M
Operating income
-$185.16M
Net income
-$209.5M
Gross margin
76.6%
Net margin
-653.7%
BCRX's net margin has shrunk by 170% YoY but it is up by 36% QoQ
The operating margin has plunged by 148% YoY but it has grown by 41% from the previous quarter
The net income has dropped by 81% year-on-year and by 15% since the previous quarter
BCRX's revenue has soared by 80% QoQ but it is down by 33% YoY

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
95.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.52
BCRX's EPS is down by 33% YoY and by 10% from the previous quarter
The P/S is 145% higher than the last 4 quarters average of 38.3
BCRX's revenue has soared by 80% QoQ but it is down by 33% YoY

Efficiency

How efficient is Biocryst Pharmaceuticals business performance
BCRX's ROS has plunged by 167% YoY but it is up by 39% from the previous quarter
The ROIC rose by 34% QoQ and by 27% YoY
The company's return on assets rose by 7% YoY and by 2.1% QoQ

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 21% lower than its total liabilities
The total liabilities has soared by 170% YoY
Biocryst Pharmaceuticals's total assets has surged by 108% YoY but it has decreased by 15% QoQ
BCRX's debt to equity has dropped by 117% year-on-year but it has surged by 73% since the previous quarter
BCRX's debt is up by 3.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.